Compare QUBT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUBT | NUVB |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | N/A | N/A |
| Metric | QUBT | NUVB |
|---|---|---|
| Price | $12.34 | $9.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $17.00 | $10.63 |
| AVG Volume (30 Days) | ★ 18.3M | 6.8M |
| Earning Date | 11-14-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $546,000.00 | ★ $26,748,000.00 |
| Revenue This Year | $135.36 | $609.55 |
| Revenue Next Year | $373.64 | $197.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 41.45 | ★ 1137.19 |
| 52 Week Low | $4.37 | $1.54 |
| 52 Week High | $25.84 | $9.53 |
| Indicator | QUBT | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 75.33 |
| Support Level | $10.13 | $8.13 |
| Resistance Level | $11.42 | $8.95 |
| Average True Range (ATR) | 1.04 | 0.53 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 62.96 | 90.68 |
Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.